China Clears Harbour BioMed's AI-Designed Obesity Antibody LET003 for Human Trials
China's NMPA accepted Harbour BioMed's IND for LET003, the first antibody from its Hu-mAtrIx AI platform, targeting obesity via dual ACVR2A/2B blockade — with only preclinical evidence so far.
